Mariner’s Immunome IMNM Stock Holding History

Mariner’s Portfolio IMNM Stock Details IMNM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-34,739	Closed	-$508K	–	3450
2024 Q3	$508K	Buy	+34,739	New	+$494K	﹤0.01%	2115

Other funds holding IMNM

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Mariner's IMNM Position: Q4 2024 in Review

Mariner sold out of Immunome (IMNM) in Q4 2024, closing a stake of 34,739 shares — an estimated $508K sold.

Mariner first reported a position in IMNM in Q3 2024 and held it in 1 quarter. The position peaked at $508K in Q3 2024. 120 funds tracked by Wall St. Rank hold IMNM as of Q4 2024.

Mariner reported no remaining Immunome position as of Q4 2024 after selling out during the quarter.
Mariner sold 34,739 Immunome shares in Q4 2024, an estimated $508K.
Mariner first reported a position in Immunome in Q3 2024 and held it in 1 quarter.
Mariner's Immunome position peaked at $508K in Q3 2024.
120 funds tracked by Wall St. Rank held Immunome as of Q4 2024.

Based on Mariner's 13F filing for Q4 2024, filed 13 Feb 2025.